Stay updated with breaking news from Gregory Vidal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts explore the efficacy and safety profiles of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment.
An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.
An expert explained how next-generation sequencing can help patients with metastatic breast cancer understand their disease and available treatment options.
Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.